| Ticker Symbol: | EBS |
|---|---|
| Exchange: | NYSE |
| Contact Info: | 2273 Research Boulevard Rockville MD 20850 301 795-1800 |
| CEO/President: | |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission - to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThrax' (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. |
| Shares Outstanding: | 29,810 (000) | Market Value: | 547,590 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 28.39% | Number of Inst.Shareholders: | 55.10% |
| Last Quarter Sales: | 56.60 ($Mil.) | Last Quarter Net Income: | 10.39 ($Mil.) |
| Last Quarter EPS: | 0.34 | P/E Ratio: | 12 |
| Most Recent Earnings: | 0.35 on 11/06/08 | Earnings Per Share: | 1.57 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN INC. | +9.10 | 56.09 | |
| GILEAD SCIENCES | -1.80 | 45.91 | |
| CELGENE CORPORA | -8.00 | 58.56 | |
| BIOGEN IDEC INC | -31.90 | 43.13 | |
| STEMCELLS INC. | -56.40 | 1.23 |
